Wednesday, January 08, 2025 The MAC22 trial (ECOG-ACRIN EA1151) tomosynthesis mammographic imaging screening trial (TMIST) has closed to accrual having reached the goal of 108,508 participants enrolled across North America. Congratulations to our Canadian sites who contributed almost 13 percent of the total accrual for this intergroup trial. Ongoing assessments for the enrolled participants will continue.TMIST was the first randomized trial to compare two types of digital mammography for breast cancer screening: tomosynthesis (known as three-dimensional, or 3-D) and conventional (two-dimensional, or 2-D). Although 3-D mammography, is a newer technology it will likely detect more findings that require follow-up, it is also likely to lead to more procedures and treatments. It is not known if this newer mammography technology is reducing a woman’s risk of developing a life-threatening (advanced) cancer compared with 2-D mammography.To find out more about the trial visit the CCTG MAC22 trial page.
